Related Experiment Video
Updated: Aug 4, 2026
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Clinical development of allogeneic chimeric antigen receptor αβ-T cells
Christos Georgiadis1, Roland Preece1, Waseem Qasim1
1University College London Great Ormond Street Institute of Child Health, Zayed Centre for Research, 20 Guilford Street, London WC1N 1DZ, UK.
Summary
Ready-made allogeneic chimeric antigen receptor (CAR) T cells offer accessible therapies. Genome engineering improves universal donor CAR T-cell safety, persistence, and function for blood cancer treatment.
Area of Science:
- Immunology
- Cellular Therapy
- Genome Engineering
Background:
- Allogeneic CAR T-cell therapies offer accessible, cost-effective treatments.
- Overcoming allogeneic barriers is crucial for universal donor cell efficacy.
Purpose of the Study:
- To review strategies for developing off-the-shelf allogeneic CAR T-cell therapies.
- To highlight genome engineering's role in enhancing universal donor CAR T-cell products.
Main Methods:
- Utilizing cell engineering platforms like RNA interference, protein restriction, and CRISPR-Cas genome editing.
- Disrupting T-cell receptor expression and removing residual cells to mitigate alloreactivity.
- Employing lymphodepletion and engineering for immune evasion and enhanced persistence.
Main Results:
- Strategies effectively mitigate alloreactivity and graft-versus-host disease risks.
- Engineered cells demonstrate improved immune evasion and resistance to lymphodepletion.
- Early studies in blood malignancies show promising clinical responses.
Conclusions:
- Off-the-shelf universal donor CAR T cells represent a viable alternative to autologous approaches.
- Genome engineering is key to improving the safety, persistence, and function of allogeneic CAR T-cell products.
